Business Context and Reporting Period
Boundless Bio, Inc. (Nasdaq: BOLD) filed a Current Report on Form 8-K dated April 13, 2026. The Company, incorporated in Delaware and headquartered in San Diego, California, is an emerging growth company. This filing reports the termination of a material definitive agreement regarding its primary laboratory and office space.
Key Financial Metrics and Transaction Details
This filing does not report standard operating financial metrics such as revenue, profit, cash flow, or margins. The primary financial impact disclosed is a one-time transaction cost associated with the early termination of a lease:
- Lease Modification Payment: $10.0 million payable to the landlord.
- Security Deposit Forfeiture: Approximately $0.5 million retained by the landlord.
- Total Immediate Cash Outflow: Approximately $10.5 million.
- Property Details: Termination of lease for approximately 80,168 rentable square feet at 10955 Alexandria Way, San Diego.
Material Changes Versus Prior Period
The filing discloses a material change in the Company's contractual obligations and real estate footprint:
- Lease Duration: The original lease, dated December 20, 2021, and amended in November 2024, was set to expire on October 31, 2034. The new agreement terminates the lease effective May 31, 2026, shortening the term by approximately eight years.
- Liability Creation: The Company has incurred a new direct financial obligation of $10.0 million, which was not present in prior periods.
Outlook, Risks, and Management Commentary
The filing indicates that the termination was contingent upon the landlord leasing the premises to a new tenant, a condition that has been satisfied. The Company intends to file the full text of the Lease Termination Agreement in its Quarterly Report on Form 10-Q for the quarter ending June 30, 2026. No specific forward-looking guidance regarding future revenue or operational strategy is provided in this document.
Key Facts for Investor Verification
- Verify the Company's current cash and cash equivalents to assess the impact of the $10.5 million immediate outflow.
- Confirm the Company's plans for future laboratory and office space following the May 31, 2026, surrender of the San Diego premises.
- Review the upcoming Form 10-Q for the full text of the Lease Termination Agreement to identify any additional covenants or liabilities.
- Assess whether the early termination impacts the Company's ability to execute its clinical or commercial development timelines.